Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02401867 · ClinicalTrials.gov registry record

Preventive Sexual Health Screening Among Female-to-Male (FTM) Transgender Adult Patients

A clinical trial of Sexually Transmitted Diseases and Uterine Cervical Neoplasms, sponsored by Fenway Community Health.

Completed
Registry status
150
Enrollment target
1
Study location

NCT02401867 is a study of Sexually Transmitted Diseases and Uterine Cervical Neoplasms that has completed, run by Fenway Community Health. The registered enrollment target is 150 participants, below the 1,247-participant average among 35 other Sexually Transmitted Diseases trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02401867, a study of Sexually Transmitted Diseases and Uterine Cervical Neoplasms, has completed, sponsored by Fenway Community Health.

COMPLETED
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the acceptability and effectiveness of utilizing vaginal self-swabs for HPV DNA testing as compared to provider-collected cervical swabs for HPV, as well as to investigate the prevalence of other Sexually Transmitted Infections (STIs) among sexually active female-to-male (FTM) transgender adults.

Study Locations (1)

Massachusetts

  • Fenway Community Health - Boston

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2015-01
Est. Completion 2016-09

Sponsor

Fenway Community Health

14 total trials

What the Registry Record Tells You About NCT02401867

The ClinicalTrials.gov registry entry for NCT02401867 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,247-participant average among 35 other Sexually Transmitted Diseases trials with a reported enrollment target (88% lower). The listed sponsor is Fenway Community Health, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sexually Transmitted Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT02401867 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02401867 about?

NCT02401867 is a clinical study titled "Preventive Sexual Health Screening Among Female-to-Male (FTM) Transgender Adult Patients". The purpose of this study is to assess the acceptability and effectiveness of utilizing vaginal self-swabs for HPV DNA testing as compared to provider-collected cervical swabs for HPV, as well as to investigate the prevalence of other Sexually Transmitted Infections (STIs) among sexually active fema...

What is the current status of trial NCT02401867?

This trial is currently completed. The enrollment target is 150 participants. The study started on 2015-01. Estimated completion is 2016-09.

What conditions does trial NCT02401867 study?

This clinical trial studies the following conditions: Sexually Transmitted Diseases, Uterine Cervical Neoplasms.

Who is sponsoring clinical trial NCT02401867?

This trial is sponsored by Fenway Community Health, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02401867 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sexually Transmitted Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.